CSL initiated with an Overweight at Morgan Stanley [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
recovery for CSL Behring underpin group EPS growth of about 13% per year over the next three years, the analyst tells investors. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See Insiders' Hot Stocks on TipRanks Read More on CSLLY: Questions or Comments about the article? Write to editor@tipranks.com Arcturus Therapeutics and CSL's Kostaive COVID-19 vaccine approved in Europe CSL, Arcturus Therapeutics announce European Commission approval for Kostaive CSL Limited Earnings Call Highlights Growth and Challenges CSL Limited Reports Strong Half-Year Finan
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $74.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) was given a new $48.00 price target on by analysts at BTIG Research.MarketBeat
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at HC Wainwright from $63.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Wells Fargo & Company from $58.00 to $50.00. They now have an "overweight" rating on the stock.MarketBeat
ARCT
Earnings
- 3/6/25 - Miss
ARCT
Sec Filings
- 3/6/25 - Form 10-K
- 3/6/25 - Form 8-K
- 2/5/25 - Form SCHEDULE
- ARCT's page on the SEC website